Calcijex Patent Expiration

Calcijex is a drug owned by Abbvie Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 02, 2020. Details of Calcijex's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6051567

(Pediatric)

Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
Feb, 2020

(4 years ago)

Expired
US6274169

(Pediatric)

Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
Feb, 2020

(4 years ago)

Expired
US6265392

(Pediatric)

Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol
Feb, 2020

(4 years ago)

Expired
US6051567 Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
Aug, 2019

(5 years ago)

Expired
US6274169 Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
Aug, 2019

(5 years ago)

Expired
US6265392 Low oxygen content compositions of 1α, 25-dihydroxycholeclciferol
Aug, 2019

(5 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Calcijex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Calcijex's family patents as well as insights into ongoing legal events on those patents.

Calcijex's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Calcijex's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 02, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Calcijex Generics:

Calcitriol is the generic name for the brand Calcijex. 17 different companies have already filed for the generic of Calcijex, with Teva Parenteral having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Calcijex's generic

How can I launch a generic of Calcijex before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Calcijex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Calcijex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Calcijex -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
1 mcg/mL and 2 mcg/mL, 1 mL vials





About Calcijex

Calcijex is a drug owned by Abbvie Inc. Calcijex uses Calcitriol as an active ingredient. Calcijex was launched by Abbvie in 1986.

Approval Date:

Calcijex was approved by FDA for market use on 25 September, 1986.

Active Ingredient:

Calcijex uses Calcitriol as the active ingredient. Check out other Drugs and Companies using Calcitriol ingredient

Dosage:

Calcijex is available in injectable form for injection use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.001MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE Discontinued INJECTION
0.002MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** INJECTABLE Discontinued INJECTION